BG100863A - Методи и фармацевтични състави за инхибиране на тромбообразуване - Google Patents

Методи и фармацевтични състави за инхибиране на тромбообразуване

Info

Publication number
BG100863A
BG100863A BG100863A BG10086396A BG100863A BG 100863 A BG100863 A BG 100863A BG 100863 A BG100863 A BG 100863A BG 10086396 A BG10086396 A BG 10086396A BG 100863 A BG100863 A BG 100863A
Authority
BG
Bulgaria
Prior art keywords
fibrin
antibody
specifil
antithrombotic agent
methods
Prior art date
Application number
BG100863A
Other languages
English (en)
Other versions
BG62476B1 (bg
Inventor
Paul Gargan
Original Assignee
American Biogenetic Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Biogenetic Sciences, Inc. filed Critical American Biogenetic Sciences, Inc.
Publication of BG100863A publication Critical patent/BG100863A/bg
Publication of BG62476B1 publication Critical patent/BG62476B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретението е приложимо в хуманната медицина заинхибиране на тромбообразуването в мястото на увреждането на кръвоносния съд. По метода се прилага фибрин-специфично моноклонално антитяло или фрагменти, или негови производни, като фрагментите и производните съдържат свързващия сектор от антитялото. Изобретението се отнася и до фармацевтичен състав, съдържащ фибрин-специфично моноклонално антитяло, или фрагмент, или производно от него, и фармацевтично-приложим носител, в достатъчно ефективно количество за инхибиране на тромбообразуването, както и до фармацевтични китове, съдържащи един или повече от компонентите на фармацевтичните състави.
BG100863A 1994-02-24 1996-09-23 Методи и фармацевтични състави за инхибиране натромбообразуване BG62476B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/204,015 US5487892A (en) 1994-02-24 1994-02-24 Method for treating thrombotic disease using a fibrin specific monoclonal antibody
PCT/US1995/001825 WO1995022986A1 (en) 1994-02-24 1995-02-21 Fibrin-specific antibody for use as an antithrombotic agent

Publications (2)

Publication Number Publication Date
BG100863A true BG100863A (bg) 1997-08-29
BG62476B1 BG62476B1 (bg) 1999-12-30

Family

ID=22756260

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100863A BG62476B1 (bg) 1994-02-24 1996-09-23 Методи и фармацевтични състави за инхибиране натромбообразуване

Country Status (26)

Country Link
US (1) US5487892A (bg)
EP (1) EP0749320A4 (bg)
JP (1) JPH09509429A (bg)
KR (1) KR970701063A (bg)
CN (1) CN1146157A (bg)
AU (1) AU708897B2 (bg)
BG (1) BG62476B1 (bg)
BR (1) BR9506949A (bg)
CA (1) CA2183953A1 (bg)
CZ (1) CZ246496A3 (bg)
FI (1) FI963288A (bg)
GE (1) GEP20002257B (bg)
HU (1) HUT76536A (bg)
LT (1) LT4192B (bg)
LV (1) LV11784B (bg)
MD (1) MD1521G2 (bg)
MX (1) MX9603602A (bg)
NO (1) NO963497L (bg)
NZ (1) NZ281481A (bg)
PL (1) PL316005A1 (bg)
RU (1) RU2152801C2 (bg)
SG (1) SG53279A1 (bg)
SK (1) SK108496A3 (bg)
TJ (1) TJ301B (bg)
UA (1) UA41984C2 (bg)
WO (1) WO1995022986A1 (bg)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5453359A (en) * 1988-06-13 1995-09-26 American Biogenetic Sciences, Inc. Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers
US5817768A (en) * 1995-06-07 1998-10-06 The New York Blood Center, Inc. Monospecific antibodies against a subunit of fibrinogen
US6727102B1 (en) 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
IL134828A0 (en) * 2000-03-01 2001-05-20 Eship 4U Com Inc System for delivery and receipt of dispatches especially useful for e-commerce
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
US7829294B2 (en) * 2004-12-28 2010-11-09 Daiichi Pure Chemicals Co., Ltd. Anti-human soluble fibrin monoclonal antibody and immunological assay method using the antibody
EP2704751B1 (en) 2011-05-02 2019-04-17 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
EP2885002A4 (en) 2012-08-14 2016-04-20 Ibc Pharmaceuticals Inc BISPECIFIC ANTIBODIES REDIRECTED AGAINST T CELLS FOR THE TREATMENT OF DISEASES
CA3177936A1 (en) 2012-12-13 2014-06-19 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
CN110563258A (zh) * 2019-09-06 2019-12-13 广东石油化工学院 一种猪场废水厌氧产氢与达标排放处理方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU572125B2 (en) * 1983-03-17 1988-05-05 Mabco Limited Monoclonal antibodies with specificity for crosslinked fibrin and their diagnotic uses
US4722903A (en) * 1983-11-14 1988-02-02 New York Blood Center, Inc. Monoclonal antibodies specific to in vivo fragments derived from human fibrinogen, human fiberin I or human fibrin II
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
WO1987006240A1 (en) * 1986-04-14 1987-10-22 The General Hospital Corporation Heterobifunctional antibodies and method of use
AU7912887A (en) * 1986-08-25 1988-03-24 American Biogenetic Sciences, Inc. Monoclonal antibodies to fibrin
DE3701812A1 (de) * 1987-01-22 1988-08-04 Max Planck Gesellschaft Fibrinspezifischer antikoerper, verfahren zur seiner herstellung und seine verwendung
US5091512A (en) * 1988-06-13 1992-02-25 American Biogenetic Sciences, Inc. Fibrinogen-specific monoclonal antibody
US5223410A (en) * 1988-06-13 1993-06-29 American Biogenetic Sciences, Inc. Method for production of antibodies utilizing an antigen-free animal
US5120834A (en) * 1988-06-13 1992-06-09 American Biogenetic Sciences, Inc. Fibrin-specific monoclonal antibody
EP0710720A1 (en) * 1988-06-13 1996-05-08 American Biogenetic Sciences, Inc. Method for the production of monoclonal antibodies utilizing a germfree animal
US5206140A (en) 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
CA2052283A1 (en) * 1990-09-27 1992-03-28 Edgar Haber Recombinant hybrid immunoglobulin molecules and method of use

Also Published As

Publication number Publication date
JPH09509429A (ja) 1997-09-22
EP0749320A4 (en) 1997-06-18
AU1843495A (en) 1995-09-11
NO963497D0 (no) 1996-08-22
MD960334A (en) 1997-09-30
CZ246496A3 (en) 1997-04-16
EP0749320A1 (en) 1996-12-27
BG62476B1 (bg) 1999-12-30
LV11784B (en) 1997-12-20
WO1995022986A1 (en) 1995-08-31
MD1521F2 (en) 2000-08-31
HUT76536A (en) 1997-09-29
MX9603602A (es) 1997-05-31
NO963497L (no) 1996-10-16
CA2183953A1 (en) 1995-08-31
UA41984C2 (uk) 2001-10-15
LT4192B (en) 1997-07-25
SG53279A1 (en) 1998-09-28
AU708897B2 (en) 1999-08-12
GEP20002257B (en) 2000-10-25
FI963288A0 (fi) 1996-08-23
US5487892A (en) 1996-01-30
NZ281481A (en) 1998-07-28
TJ301B (en) 2001-08-06
PL316005A1 (en) 1996-12-23
FI963288A (fi) 1996-08-23
LT96140A (en) 1997-03-25
BR9506949A (pt) 1997-09-23
KR970701063A (ko) 1997-03-17
RU2152801C2 (ru) 2000-07-20
HU9602337D0 (en) 1996-10-28
SK108496A3 (en) 1997-10-08
CN1146157A (zh) 1997-03-26
LV11784A (lv) 1997-06-20
MD1521G2 (ro) 2001-03-31

Similar Documents

Publication Publication Date Title
CA2234282A1 (en) Drug-resin complexes stabilized by chelating agents
MY118068A (en) Protein kinase c inhibitor
BG102583A (bg) Фенилтиазолови производни с антихерпесвирусни свойства
HUP9902068A3 (en) Methods and compositions for the diagnosis and treatment of cancer
MX9707570A (es) Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria.
MXPA01005545A (es) Composicion y metodo para tratamiento de cancer que usan moduladores de transduccion de senales y aceites esenciales vegetales naturales.
ATE233762T1 (de) Bicyclische polyamiosaure metallkomplexe, verfahren zu ihrer herstellung und ihre verwendung für medizinische bilderzeugung
IL127918A0 (en) Novel amino sugar and related sugar derivatives of indolylopyrrolocarbazoles their use as antitumor agents and pharmaceutical formulations
BG100863A (bg) Методи и фармацевтични състави за инхибиране на тромбообразуване
PL306173A1 (en) Novel inclusion complexes, method of obtaining them and pharmaceutical agent
BG104698A (bg) Глюкокортикоидселективни противовъзпалителни средства
EP0793660A4 (en) 2-SUBSTITUTED 1,2,5-THIADIAZOLIDIN-3-ON-1,1-DIOXIDES, COMPOSITION AND THEIR USE
IL141686A0 (en) Methods of treating hypertension and compositions for use therein
AU1575697A (en) Compositions and methods for the treatment and diagnosis of cancer
BG102623A (bg) Нови производни на бензоилгуанидина, методи за тяхното получаване и приложението им за производството на ле- карствени средства
AU4797596A (en) Use of hydrofluoroalkenes as cleaning agents, and compositions which may be used for their purpose
PH30665A (en) Aminosulfonyl urea acat inhibitors
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
IL147123A0 (en) Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
EP0743861A4 (en) RADIOACTIVELY MARKED ANNEXINS
MXPA98005238A (es) Agentes productores de imagenes cardiovasculares y de trombo, metodos y equipo.
AU2001271284A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
ZA949564B (en) Method for treating constipation using dimeticone.
BG102238A (bg) Нови имидазолин-2,4-диони с антиконвулсивно действие, съдържащи в 1-ва позиция един ортозаместен ар(алк)илов радикал, и метод за тяхното получаване